Categories: Eye diseases, Immune diseases, Infectious diseases, Rare diseases, Skin diseases

Aliases & Classifications for Onchocerciasis

MalaCards integrated aliases for Onchocerciasis:

Name: Onchocerciasis 12 74 52 58 54 3 43 15 17 71 32
River Blindness 52 3
Infection by Onchocerca Volvulus 12
Onchocerca Volvulus Infection 12
Onchocerciasis, Ocular 71
Robles' Disease 52
Volvulosis 12


Orphanet epidemiological data:

Inheritance: Not applicable; Age of onset: All ages;


Orphanet: 58  
Rare infectious diseases

External Ids:

Disease Ontology 12 DOID:11678
ICD9CM 34 125.3
MeSH 43 D009855
NCIt 49 C34861
SNOMED-CT 67 38539003
ICD10 32 B73
MESH via Orphanet 44 D009855 D015827
ICD10 via Orphanet 33 B73
UMLS via Orphanet 72 C0029001 C0029002
Orphanet 58 ORPHA2737
UMLS 71 C0029001 C0029002

Summaries for Onchocerciasis

NIH Rare Diseases : 52 Onchocerciasis is a rare tropical parasitic disease transmitted by a black fly. Infection by the parasite can cause eye and skin problems. In humans, the parasitic worms live under the skin (subcutaneous nodules) and produce larvae (microfilariae). The larvae are found throughout the body, but especially in the skin and eyes. Repeated bites by infected flies increase the number of adult worms and larvae. Chronic skin onchocerciasis (onchodermatitis) causes itching, a rash with small pimples (papular rash), scarring, and thickened, leathery skin (lichenification). Other symptoms may develop over time and might include saggy skin (such as ''hanging groin''), patchy areas of much lighter colored skin (leopard skin), ichthyosis -like lesions (''lizard skin''), darkening of the skin, and very severe itching. The eye infection is known as river blindness because the blackfly carrying the parasite lives near fast-flowing waters. Symptoms of an eye infection may include itchy eyes, red eyes , and sensitivity to light (photophobia ). In some cases, the larvae may infect the optic nerve. As the common name suggests, infection of the eye by onchocerciasis can lead to vision loss and eventually blindness. The disease is caused by the parasitic worm Onchocerca volvulus and is transmitted by the bite of an infected black fly. About 90% of the cases occur in Africa. Treatment aims to remove the larvae (microfilariae), to improve symptoms, to prevent progression of eye lesions, and to stop the parasite from being passed back to black flies so other people do not become infected. Medications include an anti-parasitic known as ivermectin , antibiotics such as rifampin , azithromycin , and doxycycline , and, another recently approved anti-parasitic drug, Moxidectin.

MalaCards based summary : Onchocerciasis, also known as river blindness, is related to loiasis and filariasis. An important gene associated with Onchocerciasis is IL5 (Interleukin 5), and among its related pathways/superpathways are Innate Immune System and PEDF Induced Signaling. The drugs Ivermectin and Diethylcarbamazine have been mentioned in the context of this disorder. Affiliated tissues include skin, eye and testes, and related phenotypes are hematopoietic system and immune system

Disease Ontology : 12 A filariasis that involves parasitic infection caused by the nematode Onchocerca volvulus, which is transmitted to humans through the bite of a blackfly of the genus Simulium. The worms spread throughout the body and, when they die, cause intense itching and a strong immune system response that can destroy nearby tissue. The symptoms include pruritus, dermatitis, blindness, onchocercomata (subcutaneous nodules), and lymphadenopathy.

CDC : 3 Onchocerciasis, or River Blindness, is a neglected tropical disease (NTD) caused by the parasitic worm Onchocerca volvulus. It is transmitted through repeated bites by blackflies of the genus Simulium. The disease is called River Blindness because the blackfly that transmits the infection lives and breeds near fast-flowing streams and rivers and the infection can result in blindness. In addition to visual impairment or blindness, onchocerciasis causes skin disease, including nodules under the skin or debilitating itching. Worldwide onchocerciasis is second only to trachoma as an infectious cause of blindness.

Wikipedia : 74 Onchocerciasis, also known as river blindness, is a disease caused by infection with the parasitic worm... more...

Related Diseases for Onchocerciasis

Diseases related to Onchocerciasis via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 343)
# Related Disease Score Top Affiliating Genes
1 loiasis 32.5 SRCIN1 IL5 IL4 IL13
2 filariasis 31.5 LGALS3BP IL5 IL2 CCL5
3 filarial elephantiasis 31.1 SRCIN1 IL5 IL4 IL13
4 sclerosing keratitis 31.1 SRCIN1 RBP3
5 uveitis 31.1 RBP3 IL4 IL2 CCL11
6 cytokine deficiency 31.0 IL5 IL13
7 chorioretinitis 30.9 SRCIN1 RBP3 IL2
8 schistosomiasis 30.6 RNASE3 IL5 IL4 IL2 IL13 CCL5
9 wells syndrome 30.6 RNASE3 IL5 IL2
10 cellulitis 30.5 RNASE3 IL5 DSG1
11 leprosy 3 30.5 IL5 IL4 IL2 HLA-DQA1 CSF2
12 tetanus 30.5 IL5 IL4 IL2 IL13 CSF2
13 ige responsiveness, atopic 30.4 RNASE3 IL5 IL4 IL13
14 urinary schistosomiasis 30.4 RNASE3 IL5 IL4 IL13 EPX
15 stomatitis 30.3 IL4 IL2 CSF2
16 strongyloidiasis 30.2 LGALS3BP IL5 IL13 CCL11
17 trypanosomiasis 30.1 IL4 IL2 CCL5 CALR
18 ascaris lumbricoides infection 30.1 SERPINA3 IL5 IL13
19 chagas disease 30.0 IL4 IL2 CCL5 CALR
20 posterior uveitis 30.0 RBP3 IL5 IL4 IL2 IL13
21 scleritis 29.9 SRCIN1 IL5 IL4
22 conjunctivitis 29.9 RNASE3 IL5 IL4 IL2 IL13 EPX
23 hypereosinophilic syndrome 29.9 RNASE3 IL5 IL4 IL2 IL13 EPX
24 severe combined immunodeficiency 29.8 IL5 IL4 IL2 IL13 CSF2
25 immune deficiency disease 29.7 IL4 IL2 IL13 CSF2 CCL5
26 intestinal schistosomiasis 29.7 SRCIN1 IL5 IL4 IL13
27 allergic conjunctivitis 29.7 RNASE3 IL5 IL4 IL2 IL13 CCL11
28 dermatitis 29.6 RNASE3 IL5 IL4 IL2 IL13 DSG1
29 rubella 29.6 IL5 IL4 IL2 HLA-DQA1 CALR
30 elephantiasis 29.4 SRCIN1 SERPINA3 RNASE3 IL5 IL4 ELANE
31 keratoconjunctivitis 29.4 RNASE3 IL5 IL4 IL2 IL13 CCL5
32 eosinophilic pneumonia 29.3 RNASE3 IL5 IL4 IL13 CSF2 CCL5
33 sarcoidosis 1 29.3 SERPINA3 IL2 IL13 CCL5
34 leishmaniasis 29.3 MPI IL5 IL4 IL2 IL13 HLA-DQA1
35 eye disease 29.2 SERPINA3 RBP3 IL5 IL4 IL2 IL13
36 skin disease 28.8 SERPINA3 RNASE3 IL5 IL4 IL2 IL13
37 pulmonary eosinophilia 28.7 RNASE3 IL5 IL4 IL13 EPX CSF2
38 allergic hypersensitivity disease 28.7 RNASE3 IL5 IL4 IL2 IL13 FCER2
39 autoimmune disease 28.2 RBP3 IL5 IL4 IL2 IL13 HLA-DQA1
40 parasitic helminthiasis infectious disease 28.1 SRCIN1 SERPINA3 RNASE3 IL5 IL4 IL2
41 malaria 27.6 RNASE3 IL5 IL4 IL2 IL13 FCER2
42 dermatitis, atopic 27.1 SERPINA3 RNASE3 IL5 IL4 IL2 IL13
43 volvulus of midgut 11.2
44 yemenite deaf-blind hypopigmentation syndrome 11.0
45 keratitis, hereditary 10.7
46 epilepsy 10.6
47 1-chloro-2,4-dinitrobenzene allergic contact dermatitis 10.6 IL4 IL2
48 virus associated hemophagocytic syndrome 10.5 IL4 IL2
49 punctate epithelial keratoconjunctivitis 10.5
50 loeffler endocarditis 10.5 RNASE3 IL5

Graphical network of the top 20 diseases related to Onchocerciasis:

Diseases related to Onchocerciasis

Symptoms & Phenotypes for Onchocerciasis

MGI Mouse Phenotypes related to Onchocerciasis:

# Description MGI Source Accession Score Top Affiliating Genes
1 hematopoietic system MP:0005397 9.7 CCL11 CCL5 CSF2 ELANE EPX FCER2
2 immune system MP:0005387 9.4 CCL11 CCL5 CSF2 ELANE EPX FCER2

Drugs & Therapeutics for Onchocerciasis

Drugs for Onchocerciasis (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 57)
# Name Status Phase Clinical Trials Cas Number PubChem Id
Ivermectin Approved, Investigational, Vet_approved Phase 4 70288-86-7 6474909
Diethylcarbamazine Approved, Investigational, Vet_approved Phase 4 90-89-1 3052
3 Antiparasitic Agents Phase 4
4 Anti-Infective Agents Phase 4
5 Anthelmintics Phase 4
6 Anticonvulsants Phase 4
7 Vitamins Phase 3
8 Antiprotozoal Agents Phase 3
9 Antimitotic Agents Phase 3
10 Milbemycin Phase 3
Valproic acid Approved, Investigational Phase 2 99-66-1 3121
Phenytoin Approved, Vet_approved Phase 2 57-41-0 1775
Azithromycin Approved Phase 2 83905-01-5 55185 447043
Rifampicin Approved Phase 2 13292-46-1 5458213 5381226
Pyridoxine Approved, Investigational, Nutraceutical, Vet_approved Phase 2 65-23-6 1054
Folic acid Approved, Nutraceutical, Vet_approved Phase 2 59-30-3 6037
Piperaquine Experimental, Investigational Phase 2 4085-31-8 5079497
Dihydroartemisinin Experimental, Investigational Phase 2 71939-50-9 6918483
19 Trace Elements Phase 2
20 Tranquilizing Agents Phase 2
21 Neurotransmitter Agents Phase 2
22 Micronutrients Phase 2
23 Vitamin B Complex Phase 2
24 Nutrients Phase 2
25 Vitamin B 6 Phase 2
26 Sodium Channel Blockers Phase 2
27 GABA Agents Phase 2
28 Psychotropic Drugs Phase 2
29 Vitamin B9 Phase 2
30 Folate Phase 2
31 Antimanic Agents Phase 2
32 Central Nervous System Depressants Phase 2
33 Diuretics, Potassium Sparing Phase 2
34 Antitubercular Agents Phase 2
35 Cytochrome P-450 CYP3A Inducers Phase 2
36 Antibiotics, Antitubercular Phase 2
37 Anti-Bacterial Agents Phase 2
38 Artemisinins Phase 2
39 Antimalarials Phase 2
40 Artemisinine Phase 2
41 Imatinib Mesylate Phase 2 220127-57-1 123596
42 Protein Kinase Inhibitors Phase 2
43 Adjuvants, Immunologic Phase 2
44 Antirheumatic Agents Phase 2
45 Immunologic Factors Phase 2
Pyridoxal Experimental, Nutraceutical Phase 2 66-72-8 1050
Romidepsin Approved, Investigational Phase 1 128517-07-7 5352062
Emodepside Investigational, Vet_approved Phase 1 155030-63-0
Piperazine Approved, Vet_approved 110-85-0 4837
Mebendazole Approved, Vet_approved 31431-39-7 4030

Interventional clinical trials:

(show all 33)
# Name Status NCT ID Phase Drugs
1 Ivermectin Treatment in Patients With Onchocerciasis-associated Epilepsy: A Randomized Clinical Trial Completed NCT03052998 Phase 4 Ivermectin
2 OAETREAT Extra Ivermectin Treatment of Persons With Onchocerciasis-associated Epilepsy: a Completed NCT03852303 Phase 4 ivermectin
3 Comparison Between the Post-Treatment Reactions After Single-dose Ivermectin or DEC in Subjects With Loa Loa Infection Completed NCT01593722 Phase 4 Diethylcarbamazine;Ivermectin
4 A Single-Dose, Ivermectin-Controlled, Double-Blind, Efficacy, Safety And Tolerability Study Of Orally Administered Moxidectin In Subjects Infected With Onchocerca Volvulus Completed NCT00790998 Phase 3 Moxidectin;Ivermectin
5 Comparison of Ivermectin Alone With Albendazole (ALB) Plus Ivermectin (IVM) in Their Efficacy Against Onchocerciasis in the Volta Region, Ghana. Completed NCT02078024 Phase 3 IVM plus ALB;IVM
6 Comparison of Ivermectin Alone With Albendazole (ALB) Plus Ivermectin (IVM) in Their Efficacy Against Onchocerciasis Completed NCT03238131 Phase 3 Ivermectin;Albendazole
7 A Randomized, Double Blind, Parallel Trial in the Democratic Republic of Congo (DRC) Comparing the Safety and Efficacy of Annual or Biannual Doses of Moxidectin or Ivermectin for Treatment of Onchocerciasis Not yet recruiting NCT03876262 Phase 3 Moxidectin;Ivermectin
8 Treatment of Nodding Syndrome - A Randomized Blinded Placebo-Controlled Crossover Trial of Oral Pyridoxine and Conventional Anti-Epileptic Therapy, in Northern Uganda — 2012 Unknown status NCT01730313 Phase 2 Pyridoxine;Sodium Valproate;Phenytoin;Placebo
9 A Randomized, Single-Ascending Dose, Ivermectin-Controlled, Double-Blind, Safety, Tolerability, Pharmacokinetic, and Efficacy Study Of Orally Administered Moxidectin In Subjects With Onchocerca Volvulus Infection Completed NCT00300768 Phase 2 2 mg moxidectin;ivermectin 150 mcg/kg;4 mg moxidectin;8 mg moxidectin
10 Trial of Rifampin and Azithromycin for Treatment of Endosymbiotic Bacteria (Wolbachia) in Onchocerca Volvulus in Guatemala Completed NCT00127504 Phase 2 Rifampin;Azithromycin
11 Efficacy and Safety of High-dose Ivermectin for Reducing Malaria Transmission: A Dose Finding Study (IVERMAL) Completed NCT02511353 Phase 2 ivermectin;placebo;dihydroartemisinin-piperaquine
12 A Double-Blinded, Randomized, Placebo-Controlled Dose Escalation Study to Examine the Microfilaricidal Kinetics and Safety of Imatinib for the Treatment of Loa Loa (A Pilot Study) Recruiting NCT02644525 Phase 2 Imatinib Mesylate;Placebo
13 Safety and Efficacy of Combination Therapy With Ivermectin, Diethylcarbamazine, and Albendazole (IDA) for Individuals With Onchocerciasis Recruiting NCT04188301 Phase 2 IVM w/ ALB;Single dose of IDA;Three daily doses of IDA
14 Randomized Clinical Trial, Double-blind, Single-dose Drug and Escalating Infection Intensities, Evaluating the Safety and Efficacy of Moxidectin 2 mg, Ivermectin-controlled, in Loa Loa Microfilaremic Patients Not yet recruiting NCT04049851 Phase 2 Moxidectin 2 MG Oral Tablet;Ivermectin 3Mg Tab;Placebo oral tablet
15 Randomized Clinical Trial, Double-blind, Dose-escalating of Drug Intensities, Evaluating the Safety and Efficacy of Levamisole in Loa Loa Microfilaremic Patients Not yet recruiting NCT04049630 Phase 2 LEV 1 mg/kg;LEV 1,5 mg/kg;Placebo
16 A Single-Center, Open-Label, Single-Dose Study To Assess The Pharmacokinetics, Safety, And Tolerability Of Moxidectin In Subjects Aged 4 To 11 Years ( >=12 kg) With Or Without Onchocerca Volvulus Infection Withdrawn NCT01035619 Phase 2 moxidectin
17 A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Potential Effect of a Single Oral Dose of Moxidectin on the Cardiac QT Interval of Healthy Volunteers Completed NCT03012828 Phase 1 Moxidectin
18 A Phase 1, Blinded, Randomized, Placebo Controlled, Parallel-Group, Single-Dose, Dose-Escalation Study to Investigate Safety, Tolerability, and Pharmacokinetics of Emodepside (BAY 44-4400) After Oral Dosing in Healthy Male Subjects Completed NCT02661178 Phase 1 emodepside (BAY 44-4400);placebo
19 An Open-label Study of the Pharmacokinetics and Safety of a Single Dose of Moxidectin Per Oral in Subjects Aged 4 to 17 Years With (or at Risk of) Onchocerciasis to Identify an Optimal Dose for Treatment of Children 4 to 11 Years Not yet recruiting NCT03962062 Phase 1 Moxidectin
20 Determination of the Prevalence of LF Infection in Districts Not Included in LF Control Activities and of the Basis for Integrated Implementation of LF - Onchocerciasis Elimination Strategies in Potentially Co-endemic Areas Completed NCT03131401
21 Optimization of Mass Drug Administration With Existing Drug Regimens for Lymphatic Filariasis and Onchocerciasis for Ivory Coast Completed NCT02032043 Annual versus Semiannual Albendazole plus Ivermectin MDA
22 Optimization of Mass Drug Administration With Existing Drug Regimens for Lymphatic Filariasis and Onchocerciasis for Liberia Completed NCT01905436 Annual versus Semiannual Albendazole plus Ivermectin Mass Drug Administration
23 Community-Directed Treatment in the Control of Soil-Transmitted Helminths Among Children Aged 12-59 Months in Mazabuka District of Zambia Completed NCT00349323
24 Community Based Safety Study of 2-drug (Diethylcarbamazine and Albendazole) Versus 3-drug (Ivermectin, Diethylcarbamazine and Albendazole) Therapy for Lymphatic Filariasis Completed NCT02899936 3 drug dose - IDA;2 drug dose - DA
25 Optimization of Mass Drug Administration With Existing Drug Regimens for Lymphatic Filariasis and Onchocerciasis Completed NCT01905423 Albendazole and diethylcarbamazine
26 Alternative Chemotherapies for Lymphatic Filariasis (LF) Treatment and Elimination in Africa [Cote d'Ivoire] Completed NCT02974049 Albendazole;Ivermectin;Diethylcarbamazine
27 Veron Scabies Education and Eradication Program Completed NCT00604084 Ivermectin;Permethrin 5% lotion
28 Clinical Features and Potential Etiology of Epilepsy and Nodding Syndrome in the Mahenge Area, Ulanga District Recruiting NCT03653975
29 Prevalence Survey for Innovative and Intensified Disease Management (IDM) Neglected Tropical Diseases (NTDs): A Cluster Randomised Two-stage Active Case Search for IDM-NTDs in Liberia Recruiting NCT03683745
30 When is it Appropriate to Stop? Applied Field Research to Develop an M&E Strategy to Recruiting NCT04124250
31 Host Response to Infection and Treatment in the Filarial Diseases of Humans Recruiting NCT00001230
32 Microfilarial Clearance From the Eye and Ocular Changes Associated With Ivermectin Treatment in Individuals With Onchocerciasis Active, not recruiting NCT03517462 Ivermectin 3Mg Tab
33 Evaluation of the Diagnosis Performances of DEC LTS-2 Skin Patch for Onchocerciasis in Central Africa Not yet recruiting NCT04035174

Search NIH Clinical Center for Onchocerciasis

Inferred drug relations via UMLS 71 / NDF-RT 50 :


Cochrane evidence based reviews: onchocerciasis

Genetic Tests for Onchocerciasis

Anatomical Context for Onchocerciasis

MalaCards organs/tissues related to Onchocerciasis:

Skin, Eye, Testes, T Cells, Neutrophil, Lung, Lymph Node

Publications for Onchocerciasis

Articles related to Onchocerciasis:

(show top 50) (show all 3657)
# Title Authors PMID Year
Onchocerca volvulus-specific antibody and cytokine responses in onchocerciasis patients after 16 years of repeated ivermectin therapy. 54 61
17302900 2007
Genetic polymorphism of the beta-tubulin gene of Onchocerca volvulus in ivermectin naïve patients from Cameroon, and its relationship with fertility of the worms. 54 61
16197589 2006
Antigen-specific T regulatory-1 cells are associated with immunosuppression in a chronic helminth infection (onchocerciasis). 54 61
12443893 2002
Eosinophil granule proteins in serum and urine of patients with helminth infections and atopic dermatitis. 54 61
11169280 2000
Pathophysiological roles of calreticulin in autoimmune disease. 54 61
10320638 1999
Eosinophils, eosinophil cationic protein and eosinophil-derived neurotoxin in serum and urine of patients with onchocerciasis coinfected with intestinal nematodes and in urinary schistosomiasis. 54 61
10206116 1999
Characterization of human immune responses to the cytosolic superoxide dismutase and glutathione S-transferase from Onchocerca volvulus. 54 61
9294549 1997
The diverse expression of immunity in humans at distinct states of Onchocerca volvulus infection. 54 61
9176114 1997
Serum levels of eosinophil cationic protein, eosinophil-derived neurotoxin and myeloperoxidase in infections with filariae and schistosomes. 54 61
9025985 1996
Elevations in granulocyte-macrophage colony-stimulating factor and interleukin-5 levels precede posttreatment eosinophilia in onchocerciasis. 54 61
8627086 1996
A 16mer peptide of the human autoantigen calreticulin is a most prominent HLA-DR4Dw4-associated self-peptide. 54 61
7836063 1994
Epitopes of the Onchocerca volvulus RAL1 antigen, a member of the calreticulin family of proteins, recognized by sera from patients with onchocerciasis. 54 61
7520419 1994
Regulation of IL-5 in onchocerciasis. A critical role for IL-2. 54 61
8099937 1993
Calreticulin synthetic peptide analogues: anti-peptide antibodies in autoimmune rheumatic diseases. 54 61
7680295 1993
Serological cross-reactivity between a human Ro/SS-A autoantigen (calreticulin) and the lambda Ral-1 antigen of Onchocerca volvulus. 54 61
1602002 1992
Interleukin-5 and the posttreatment eosinophilia in patients with onchocerciasis. 54 61
1918387 1991
Analysis of aqueous humour in ocular onchocerciasis. 54 61
2036808 1991
Cell-mediated immunity against human retinal extract, S-antigen, and interphotoreceptor retinoid binding protein in onchocercal chorioretinopathy. 54 61
2210999 1990
Humoral autoimmune response against S-antigen and IRBP in ocular onchocerciasis. 54 61
2365568 1990
Humoral and cell-mediated immune response against human retinal antigens in relation to ocular onchocerciasis. 54 61
2378211 1990
Survey of infection and determination of the transmission vector of Onchocerca fasciata in camels (Camelus bactrianus) in Inner Mongolia, China. 61
31508843 2020
Ivermectin concentration in breastmilk of a woman with Strongyloides stercoralis and human T-lymphotropic virus-I co-infection. 61
31678122 2020
A general method for multiscale modelling of vector-borne disease systems. 61
31897289 2020
The Galabat-Metema cross-border onchocerciasis focus: The first coordinated interruption of onchocerciasis transmission in Africa. 61
32027648 2020
Description, molecular characteristics and Wolbachia endosymbionts of Onchocerca borneensis Uni, Mat Udin & Takaoka n. sp. (Nematoda: Filarioidea) from the Bornean bearded pig Sus barbatus Müller (Cetartiodactyla: Suidae) of Sarawak, Malaysia. 61
32028994 2020
Onchocerca volvulus is not detected in the cerebrospinal fluid of persons with onchocerciasis-associated epilepsy. 61
31786246 2020
River blindness in East Africa: gains and losses. 61
31964681 2020
Macrofilaricidal Benzimidazole-Benzoxaborole Hybrids as an Approach to the Treatment of River Blindness: Part 1. Amide Linked Analogs. 61
31876154 2020
Ivermectin as a novel complementary malaria control tool to reduce incidence and prevalence: a modelling study. 61
31948767 2020
In vivo efficacy of the boron-pleuromutilin AN11251 against Wolbachia of the rodent filarial nematode Litomosoides sigmodontis. 61
31986143 2020
Safety of high-dose ivermectin: a systematic review and meta-analysis. 61
31960060 2020
Post-elimination surveillance in formerly onchocerciasis endemic focus in Southern Mexico. 61
31999704 2020
Implications for annual retesting after a test-and-not-treat strategy for onchocerciasis elimination in areas co-endemic with Loa loa infection: an observational cohort study. 61
31676244 2020
Ivermectin as an adjuvant to anti-epileptic treatment in persons with onchocerciasis-associated epilepsy: A randomized proof-of-concept clinical trial. 61
31923177 2020
First molecular detection of Onchocerca flexuosa (Wedl, 1856) in red deer in Slovakia. 61
31953565 2020
Progress in Understanding the Molecular Mechanisms Underlying the Antitumour Effects of Ivermectin. 61
32021111 2020
Natural infections with larvae of Onchocercaspecies type I in the human-biting black fly, Simulium nigrogilvum (Diptera: Simuliidae), in western Thailand. 61
31954685 2020
Biting Rates and Onchocerca Infectivity Status of Black Flies from the Simulium damnosum Complex (Diptera: Simuliidae) in Osun State, Nigeria. 61
31901168 2020
Low ivermectin use among 5- to 6-year-old children: observations from door-to-door surveys in onchocerciasis-endemic regions in Africa. 61
31251354 2020
Macrofilaricidal Benzimidazole-Benzoxaborole Hybrids as an Approach to the Treatment of River Blindness: Part 2. Ketone Linked Analogs. 61
31876143 2020
Characterization of a novel glycosylated glutathione transferase of Onchocerca ochengi, closest relative of the human river blindness parasite. 61
31190665 2019
Implementation of test-and-treat with doxycycline and temephos ground larviciding as alternative strategies for accelerating onchocerciasis elimination in an area of loiasis co-endemicity: the COUNTDOWN consortium multi-disciplinary study protocol. 61
31801631 2019
Modelling exposure heterogeneity and density dependence in onchocerciasis using a novel individual-based transmission model, EPIONCHO-IBM: Implications for elimination and data needs. 61
31805049 2019
Short-course quinazoline drug treatments are effective in the Litomosoides sigmodontis and Brugia pahangi jird models. 61
31869759 2019
Dried blood microsampling-based therapeutic drug monitoring of anti-epileptic drugs in children with nodding syndrome and epilepsy in Uganda and the Democratic Republic of the Congo. 61
31834012 2019
Frequency and distribution of neglected tropical diseases in Mozambique: a systematic review. 61
31836025 2019
Ivermectin use in children below 15 kg: potential benefits for onchocerciasis and scabies elimination programmes. 61
31693749 2019
Infectivity of Simulium damnosum s.l. and therapeutic coverage of ivermectin distribution 10 years post treatment around Owena Dam, Ondo state, Nigeria. 61
31697923 2019
Neuroinflammation and Not Tauopathy Is a Predominant Pathological Signature of Nodding Syndrome. 61
31553445 2019
Assessment of multiplex Onchocerca volvulus peptide ELISA in non-endemic tropical regions. 61
31783767 2019

Variations for Onchocerciasis

Expression for Onchocerciasis

Search GEO for disease gene expression data for Onchocerciasis.

Pathways for Onchocerciasis

Pathways related to Onchocerciasis according to GeneCards Suite gene sharing:

(show all 30)
# Super pathways Score Top Affiliating Genes
Show member pathways
Show member pathways
13.62 IL5 IL4 IL2 IL13 FCER2 CSF2
Show member pathways
13.36 IL5 IL4 IL2 IL13 CSF2 CCL7
Show member pathways
13.31 IL5 IL4 IL2 IL13 HLA-DQA1 FCER2
Show member pathways
13.24 IL5 IL4 IL2 IL13 CSF2 CCL7
Show member pathways
Show member pathways
12.65 RNASE3 IL5 IL4 IL2 IL13 HLA-DQA1
Show member pathways
12.55 IL5 IL4 IL2 IL13 HLA-DQA1
Show member pathways
12.31 IL5 IL4 IL13 CSF2 CCL7 CCL11
Show member pathways
12.3 IL5 IL4 IL2 IL13 CSF2
11 12.28 IL2 HLA-DQA1 CSF2 CALR
Show member pathways
12.27 IL2 CCL7 CCL5 CCL11
Show member pathways
14 11.96 IL5 IL4 IL2 CSF2
15 11.94 IL4 IL13 FCER2 CCL11
16 11.9 IL5 IL4 HLA-DQA1 FCER2 CSF2
17 11.79 HLA-DQA1 CSF2 CCL5
18 11.77 IL5 IL4 IL2 IL13
19 11.77 IL5 IL4 IL2 IL13 CSF2
Show member pathways
11.74 IL5 IL4 IL2 CSF2
21 11.62 IL5 IL4 FCER2 CCL11
22 11.46 IL4 IL13 FCER2 CSF2 CCL5
23 11.38 IL5 IL4 IL2 IL13 CCL11
24 11.3 IL5 IL4 IL2
25 11.28 IL5 IL4 IL13
26 11.28 IL4 IL2 IL13 CSF2 CCL5 CCL11
27 11.19 IL5 IL4 IL2 IL13
28 11.02 IL5 IL4 IL2 IL13 CSF2
29 10.94 IL5 IL4 IL2 IL13 CSF2 CCL7
30 10.9 IL5 IL4 IL13 CSF2 CCL5 CCL11

GO Terms for Onchocerciasis

Cellular components related to Onchocerciasis according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 extracellular region GO:0005576 9.86 SERPINA3 RNASE3 RBP3 LGALS3BP IL5 IL4
2 cell GO:0005623 9.7 IL2 IL13 ELANE CCL7 CCL5 CCL11
3 extracellular space GO:0005615 9.5 SERPINA3 RNASE3 RBP3 LGALS3BP IL5 IL4
4 azurophil granule lumen GO:0035578 9.43 SERPINA3 RNASE3 ELANE

Biological processes related to Onchocerciasis according to GeneCards Suite gene sharing:

(show all 23)
# Name GO ID Score Top Affiliating Genes
1 neutrophil degranulation GO:0043312 9.96 SERPINA3 RNASE3 EPX ELANE DSG1
2 MAPK cascade GO:0000165 9.88 IL5 IL2 CSF2 CCL5
3 inflammatory response GO:0006954 9.85 SERPINA3 IL5 IL13 CCL7 CCL5 CCL11
4 cellular response to interferon-gamma GO:0071346 9.79 CCL7 CCL5 CCL11
5 neutrophil chemotaxis GO:0030593 9.76 CCL7 CCL5 CCL11
6 cellular response to interleukin-1 GO:0071347 9.74 CCL7 CCL5 CCL11
7 chemokine-mediated signaling pathway GO:0070098 9.71 CCL7 CCL5 CCL11
8 positive regulation of T cell proliferation GO:0042102 9.7 IL4 IL2 CCL5
9 positive regulation of smooth muscle cell proliferation GO:0048661 9.69 IL13 ELANE CCL5
10 monocyte chemotaxis GO:0002548 9.65 CCL7 CCL5 CCL11
11 cellular calcium ion homeostasis GO:0006874 9.65 ELANE CCL7 CCL5 CCL11 CALR
12 lymphocyte chemotaxis GO:0048247 9.63 CCL7 CCL5 CCL11
13 positive regulation of B cell proliferation GO:0030890 9.62 IL5 IL4 IL2 IL13
14 dendritic cell differentiation GO:0097028 9.61 IL4 CSF2
15 immune response GO:0006955 9.61 IL5 IL4 IL2 IL13 HLA-DQA1 CSF2
16 positive regulation of podosome assembly GO:0071803 9.6 IL5 CSF2
17 positive regulation of immunoglobulin secretion GO:0051024 9.59 IL5 IL2
18 eosinophil chemotaxis GO:0048245 9.58 CCL7 CCL5 CCL11
19 positive regulation of isotype switching to IgG isotypes GO:0048304 9.55 IL4 IL2
20 positive regulation of tyrosine phosphorylation of STAT protein GO:0042531 9.55 IL4 IL2 IL13 CSF2 CCL5
21 positive regulation of natural killer cell chemotaxis GO:2000503 9.49 CCL7 CCL5
22 negative regulation of complement-dependent cytotoxicity GO:1903660 9.43 IL4 IL13
23 cytokine-mediated signaling pathway GO:0019221 9.23 IL5 IL4 IL2 IL13 FCER2 CSF2

Molecular functions related to Onchocerciasis according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 growth factor activity GO:0008083 9.56 IL5 IL4 IL2 CSF2
2 chemokine activity GO:0008009 9.5 CCL7 CCL5 CCL11
3 cytokine activity GO:0005125 9.23 IL5 IL4 IL2 IL13 CSF2 CCL7
4 CCR1 chemokine receptor binding GO:0031726 9.16 CCL7 CCL5
5 CCR chemokine receptor binding GO:0048020 9.13 CCL7 CCL5 CCL11

Sources for Onchocerciasis

9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
28 GO
29 GTR
31 HPO
32 ICD10
33 ICD10 via Orphanet
37 LifeMap
41 MedGen
43 MeSH
44 MESH via Orphanet
45 MGI
48 NCI
49 NCIt
54 Novoseek
57 OMIM via Orphanet
61 PubMed
70 Tocris
72 UMLS via Orphanet
Loading form....